KR920018215A - 류스트로덕신(leustroducsins)으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도 - Google Patents

류스트로덕신(leustroducsins)으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도 Download PDF

Info

Publication number
KR920018215A
KR920018215A KR1019920005088A KR920005088A KR920018215A KR 920018215 A KR920018215 A KR 920018215A KR 1019920005088 A KR1019920005088 A KR 1019920005088A KR 920005088 A KR920005088 A KR 920005088A KR 920018215 A KR920018215 A KR 920018215A
Authority
KR
South Korea
Prior art keywords
salt
group
streptomyces
following structural
structural formula
Prior art date
Application number
KR1019920005088A
Other languages
English (en)
Other versions
KR0145680B1 (ko
Inventor
다까후미 고하마
이사오 가네꼬
다께미찌 나까무라
게이이찌 마쓰다
다께시 가가와끼
류조 에노끼따
Original Assignee
가와무라 요시부미
상꾜 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가와무라 요시부미, 상꾜 가부시끼가이샤 filed Critical 가와무라 요시부미
Publication of KR920018215A publication Critical patent/KR920018215A/ko
Application granted granted Critical
Publication of KR0145680B1 publication Critical patent/KR0145680B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/903—Streptomyces platensis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

내용 없음

Description

류스트로덕신(LEUSTRODUCSINS)으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 구조식(Ⅰ)의 화합물 또는 그의 염 :
    〔상기 식에서 , R은 5-메틸헥사노일옥시기, 6-메틸옥타노일옥시기 또는 7-메틸옥타노일옥시기를 나타낸다〕.
  2. 제1항에 있어서, 하기 구조식(Ⅰa)을 갖는 화합물 또는 그의 염.
  3. 제1항에 있어서, 하기 구조식(Ⅰb)을 갖는 화합물 또는 그의 염.
  4. 제1항에 있어서, 하기 구조식(Ⅰc)을 갖는 화합물 또는 그의 염.
  5. 스트렙토마이세스 속의 류스트로덕신-생산 미생물을 배양하고 배양물로 부터 적어도 하나의 류스트로덕신을 채취하는 것을 특징으로 하는 제1항 내지 제4항 중 어느 한 항에 따른 적어도 하나의 류스트로덕신 또는 그의 염의 제조방법.
  6. 제5항에 있어서, 상기 미생물이 스트렙토마이세스 플라텐시스 종의 류스트로덕신-생산 균주인 방법.
  7. 제5항에 있어서, 상기 미생물이 스트렙토마이세스 플라텐시스 SANK 60191(FERM BP-3288)인 방법.
  8. 스트렙토마이세스 플라텐시스 SANK 60191(FERM BP-3288)의 분리된 배양물.
  9. 제약학적으로 허용가능한 담체 또는 희석제와 혼합된 제1항 내지 제4항 중 어느 한 항에 따른 적어도 하나의 류스트로덕신 또는 그의 염을 포함하는 제약학적 조성물.
  10. 암 화학요법 또는 방사선요법으로 인한 해로운작용, 감염, 암, 뇌 기능장애 및 진균 감염을 치료 또는 예방하기 위한, 제1항 내지 제4항 중 어느 한 항에 따른 유효량의 적어도 하나의 류스트로덕신 또는 그의 염을 상기 작용, 감염, 암 또는 기능장애에 걸려 있거나 걸리기 쉬운 포유류에 투여하는 것을 특징으로 하는 치료 또는 예방방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920005088A 1991-03-27 1992-03-27 "류스트로덕신"으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도 KR0145680B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6308791 1991-03-27
JP91-63087 1991-03-27

Publications (2)

Publication Number Publication Date
KR920018215A true KR920018215A (ko) 1992-10-21
KR0145680B1 KR0145680B1 (ko) 1998-08-01

Family

ID=13219198

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005088A KR0145680B1 (ko) 1991-03-27 1992-03-27 "류스트로덕신"으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도

Country Status (23)

Country Link
US (2) US5334587A (ko)
EP (1) EP0506463B1 (ko)
JP (1) JPH05123179A (ko)
KR (1) KR0145680B1 (ko)
CN (1) CN1058294C (ko)
AT (1) ATE134640T1 (ko)
AU (1) AU649116B2 (ko)
CA (1) CA2064126A1 (ko)
CZ (1) CZ279299B6 (ko)
DE (1) DE69208494T2 (ko)
DK (1) DK0506463T3 (ko)
ES (1) ES2086651T3 (ko)
FI (1) FI101978B1 (ko)
GR (1) GR3019996T3 (ko)
HK (1) HK117696A (ko)
HU (1) HU216875B (ko)
IE (1) IE74389B1 (ko)
IL (1) IL101394A (ko)
IS (1) IS1604B (ko)
NO (1) NO304600B1 (ko)
NZ (1) NZ242155A (ko)
RU (1) RU2082760C1 (ko)
TW (1) TW212182B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649116B2 (en) * 1991-03-27 1994-05-12 Sankyo Company Limited New compounds, named the "Leustroducins", their preparation and their therapeutic uses
ATE166058T1 (de) * 1993-04-23 1998-05-15 Sankyo Co Neue verbindung, leustroducsin h, ihre herstellung und therapeutische verwendung
AU702751B2 (en) * 1995-10-17 1999-03-04 Daiichi Suntory Pharma Co., Ltd Therapeutics for thrombocytopenia
US9861346B2 (en) 2003-07-14 2018-01-09 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
EP1667684A1 (en) * 2003-09-17 2006-06-14 ICOS Corporation Use of chk1 inhibitors to control cell proliferation
WO2008124603A1 (en) 2007-04-05 2008-10-16 Nmt Medical, Inc. Septal closure device with centering mechanism
US20130165967A1 (en) 2008-03-07 2013-06-27 W.L. Gore & Associates, Inc. Heart occlusion devices
US8956389B2 (en) 2009-06-22 2015-02-17 W. L. Gore & Associates, Inc. Sealing device and delivery system
US20120029556A1 (en) 2009-06-22 2012-02-02 Masters Steven J Sealing device and delivery system
US10828019B2 (en) 2013-01-18 2020-11-10 W.L. Gore & Associates, Inc. Sealing device and delivery system
US9808230B2 (en) 2014-06-06 2017-11-07 W. L. Gore & Associates, Inc. Sealing device and delivery system
CN113262293B (zh) * 2020-02-17 2022-11-08 中国医学科学院医药生物技术研究所 一组具有抗病毒活性的肽类化合物奥米克欣及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592925A (en) * 1969-04-21 1971-07-13 American Cyanamid Co Antibiotics ah272alpha2 and ah272beta2 and process for producing same
US3907779A (en) * 1974-05-20 1975-09-23 Upjohn Co 5,6 Dihydro-5-azathymidine and derivatives
AU574713B2 (en) * 1983-09-12 1988-07-14 Warner-Lambert Company Cl-1957a antibiotic compound and its production
US4575500A (en) * 1984-03-26 1986-03-11 Merck & Co., Inc. Antifungal substances and process for their production
JPH02186A (ja) * 1987-05-07 1990-01-05 Sumitomo Chem Co Ltd 新規化合物およびそれを有効成分とする農工業用殺菌剤
ES2080068T3 (es) * 1988-02-13 1996-02-01 Suntory Ltd Derivados de 2-piranona y su procedimiento de preparacion.
JP2865302B2 (ja) * 1988-02-13 1999-03-08 サントリー株式会社 ２―ピラノン誘導体及びその製造法並びにそれを含む抗菌剤
AU649116B2 (en) * 1991-03-27 1994-05-12 Sankyo Company Limited New compounds, named the "Leustroducins", their preparation and their therapeutic uses

Also Published As

Publication number Publication date
HU9201005D0 (en) 1992-06-29
CA2064126A1 (en) 1992-09-28
EP0506463A3 (en) 1993-01-13
TW212182B (ko) 1993-09-01
DK0506463T3 (da) 1996-06-10
NO304600B1 (no) 1999-01-18
FI921339A (fi) 1992-09-28
CN1066292A (zh) 1992-11-18
NO921158L (no) 1992-09-28
IE74389B1 (en) 1997-07-30
IL101394A0 (en) 1992-11-15
GR3019996T3 (en) 1996-08-31
US5443972A (en) 1995-08-22
EP0506463A2 (en) 1992-09-30
CZ91592A3 (en) 1993-04-14
EP0506463B1 (en) 1996-02-28
HU216875B (hu) 1999-09-28
NO921158D0 (no) 1992-03-25
IS3829A (is) 1992-09-28
IE920965A1 (en) 1992-10-07
IS1604B (is) 1996-10-18
FI921339A0 (fi) 1992-03-26
IL101394A (en) 1996-05-14
KR0145680B1 (ko) 1998-08-01
AU649116B2 (en) 1994-05-12
HK117696A (en) 1996-07-12
ATE134640T1 (de) 1996-03-15
FI101978B (fi) 1998-09-30
HUT60521A (en) 1992-09-28
FI101978B1 (fi) 1998-09-30
RU2082760C1 (ru) 1997-06-27
ES2086651T3 (es) 1996-07-01
US5334587A (en) 1994-08-02
DE69208494T2 (de) 1996-10-24
JPH05123179A (ja) 1993-05-21
CN1058294C (zh) 2000-11-08
DE69208494D1 (de) 1996-04-04
AU1312392A (en) 1992-10-01
NZ242155A (en) 1993-09-27
CZ279299B6 (cs) 1995-04-12

Similar Documents

Publication Publication Date Title
Tally et al. Metronidazole versus anaerobes—in vitro data and initial clinical observations
Finlay et al. Viomycin, a new antibiotic active against mycobacteria
KR920018215A (ko) 류스트로덕신(leustroducsins)으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도
CA2088390A1 (en) Tetrahydropyrimidine derivatives and pharmaceutical compositions containing them
KR940703923A (ko) 4,5-디히드로겔다나마이신 및 그의 하이드로퀴논의 제조 방법 및 용도(Process and Uses for 4,5-Dihydrogeldanamycin and Its Hydroquinone)
KR840007257A (ko) 레베카마이신과 그것의 제조방법
KR970705392A (ko) 신규한 항생제 조성물 및 그람-양성 세균 및 마이코플라스마 감염의 치료 방법(novel antibiotic compounds and methods to treat grampositive bacterial and mycoplasmal infections)
Hobby et al. The activity of viomycin against Mycobacterium tuberculosis and other microorganisms in vitro and in vivo
KR890002214A (ko) 데만노실 테이코플라닌 유도체
KR930004325A (ko) 3-데옥시-만노사민 유도체 및 이의 제조방법.
Nilsson et al. Frequencies of variants resistant to different aminoglycosides in Pseudomonas aeruginosa
US4191779A (en) Method of treating bacterial infections
ES2077345T3 (es) Intermediarios del grupo mureidomicina, su preparacion y su uso.
US4216227A (en) Omega-amino acid ester hydrochlorides for treating bacterial infections
TH13242EX (th) สารประกอบใหม่ชื่อว่า "เลอุสโทรดัคซิน" การเตรียมและประโยชน์ในการใช้รักษาของสารประกอบเหล่านี้
Shibamoto et al. PHARMACOLOGICAL STUDIES ON CARBAPENEM ANTIBIOTICS I. METABOLISM OF PS-5 IN ANIMAL TISSUES
KR890009936A (ko) 그리세올산 모노에스테르류, 이의 제조방법 및 용도
KR900008048A (ko) 혈소판 활성화 인자 길항물질인 "포막틴(phomacting)", 그의 제조 및 용도
KR920009986A (ko) 다이네마이신 c 항종양 항생제
KR880002844A (ko) 펜옥사지논, 이의 제조방법 및 용도
Sakai et al. Characteristics of two broad spectrum antibiotics produced by Mycoplasma SP. RP III
US3155583A (en) Antibiotic narangomycin and method of production
TH13242A (th) สารประกอบใหม่ชื่อว่า "เลอุสโทรดัคซิน" การเตรียมและประโยชน์ในการใช้รักษาของสารประกอบเหล่านี้
US3853992A (en) Antibiotic em-98
TH10202B (th) สารประกอบใหม่ชื่อว่า "เลอุสโทรดัคซิน" การเตรียมและประโยชน์ในการใช้รักษาของสารประกอบเหล่านี้

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee